William Blair analyst Andrew Brackmann has maintained their neutral stance on TEM stock, giving a Hold rating on December 15.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andrew Brackmann’s rating is based on the company’s evolving strategy in leveraging its data business, particularly through foundational model initiatives. While Tempus AI’s genomics business forms the majority of its revenue base, the long-term potential of the company depends heavily on its ability to harness its growing database and apply AI to advance the field of personalized medicine.
Despite the promising vision, the Hold rating reflects a balanced viewpoint considering potential uncertainties in scaling these initiatives effectively and their future impact on revenue growth. This cautious stance underscores the need for further evidence of execution and tangible outcomes before revising the stock rating upward.
In another report released on December 15, Bank of America Securities also reiterated a Hold rating on the stock with a $80.00 price target.